Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

I learned to heal my sadness by cradling dying chickens 

Brave Little Hunter is free: Baby orca escapes lagoon for open seas

Soldiers reunite with their pets from overseas: ‘It meant everything to me’

Attorney general moves to reclassify marijuana as lower-risk drug

Poll shows how RFK Jr.’s appeal to anti-vaccine right could hurt Trump

Views of the campus protests are too broad — and too narrow

Americans are sleeping more than ever. See how you compare.

Parenting in Gaza today is so much more than keeping your children alive

In photos: Flash floods kill over 100 people in Kenya

The FBI director’s concerns over terrorism are at ‘a whole other level’ 

U.S. campus protests spread to the Middle East and Europe  

Biden is letting Assad off the hook, with dangerous consequences

Southwest passengers now get a $75 voucher for big flight disruptions

The Rick Steves guide to life

The sad, stale state of in-flight vegetarian meals

Miss Manners: Some audience members ask rambling questions post-lecture

Carolyn Hax: Her family left all the kitchen work to her, so she went on strike

Ask Amy: Why did my friend lie about seeing my ex-girlfriend?

Apple banned this app for years. It’s now America’s No. 1 iPhone app. 

8 major newspapers join legal backlash against OpenAI, Microsoft

Fired Google workers who protested Israel deal file complaint with labor board

Nationals sweep away the Marlins to get back to .500

Jayden Daniels is latest in Washington’s checkered history of first-round QBs

The Rangers swept the Capitals, and it’s time for the new core to take charge

Trump and allies say Biden pays rent for ‘illegals’ in Michigan. Not true.

Eighty percent of Ukraine-Israel bill will be spent in U.S. or by U.S. military

Facts in the Trump courtroom v. ‘facts’ in the court of public opinion

A murder plot that cannot be ignored: India must come clean at last

How to confront antisemitism, deal with protests — and respect free speech

Is student loan debt an emergency? Take our quiz.

 Donald Trump Speaks During A Campaign Rally In Green Bay Wisconsin

On the stump, Donald Trump the candidate <a href="https://www.statnews.com/2016/03/02/trump-health-care-plan/">promised</a> big changes in the way America buys prescription drugs — allowing Medicare to negotiate drug prices directly with pharmaceutical manufacturers, and allowing Americans to buy at the prices that Canada has negotiated by importing drugs from abroad. Now Trump the president has finally unveiled <a href="https://www.hhs.gov/sites/default/files/AmericanPatientsFirst.pdf">his big drug plan</a>, and there is some confusion out there as to whether he has delivered on his promise.

On Hugh Hewitt’s radio show, Health and Human Services Secretary Alex Azar delivered a <a href="http://www.hughhewitt.com/hhs-secretary-alex-azar/">lengthy retort</a> to claims that the administration had punted on drug price negotiation: “What we are doing is more sweeping than anybody’s ever proposed before. We are enhancing the powers of the retail prescription drug program, what’s called Part D. We are unshackling these middlemen, these Part D plans, that negotiate on our behalf.”

A friend emailed Monday morning to ask what the truth was. And in case he’s not the only person confused, it seems worth explaining what Azar is saying.

In typical American fashion, when Medicare added prescription drug coverage, we didn’t do anything simple, like having the government buy a bunch of drugs and dispense them, or simply offering to reimburse drug purchases. Instead, Medicare Part D operates through private plans, each of which has its own set of drugs that it’s willing to cover. Those private plans can and do negotiate with pharmaceutical manufacturers to get discounts on those drugs. However, their ability to negotiate is limited, because Medicare <a href="https://www.ncoa.org/wp-content/uploads/part-d-drug-coverage-rules.pdf">requires</a> that every plan offer at least two treatments for a given condition — and basically every available treatment for the “six protected classes,” which include conditions such as HIV and cancer.

It’s a bit hard for drug plans to negotiate under such conditions. If manufacturers know that you are basically going to have to buy their product no matter what they charge, is it any wonder that some cancer drugs run well into the six figures?

So the administration is giving drug plans some leverage: It’s proposing to drop the number of covered drugs down to one in some categories. The proposal also contains some language about letting Part D plans negotiate prices for drugs in the “six protected classes,” though it’s not clear exactly what this means. It’s reasonable to believe that this will lower the prices of the drugs for some conditions, though it’s also reasonable to believe that this will make it harder for some seniors to get their preferred drugs.

So Azar is right that Trump’s proposal means more negotiation for Medicare drug prices. And his critics are right that this is not at all what they meant by “let Medicare negotiate drug prices.” What they meant was that they wanted the Department of Health and Human Services to engage in global drug price negotiations for the whole program, and thereby get fabulous discounts through the power of bulk purchasing.

Unfortunately, this isn’t the end of the discussion, because most of the people saying “unleash the negotiators” are confused. By itself, covering a lot of patients doesn’t give you all that much negotiating power; if it did, we’d already be enjoying some of the cheapest drug prices in the world. America’s biggest pharmaceutical benefit managers <a href="https://www.thebalancesmb.com/largest-pharmacy-benefit-managers-2663840">cover more people</a> than the entire populations of many European countries. Yet those countries get much lower prices on many drugs than we do.

How, then, do they get those savings? Through the healing magic of the word “no.” Regulators elsewhere, unlike here, have some freedom to say, “<a href="https://www.vox.com/science-and-health/2016/11/30/12945756/prescription-drug-prices-explained">Nope, your drug is simply too expensive for the benefit it delivers.</a>” This gives them a lot of leverage in negotiations, but it involves a certain amount of steely will, because in order to make it work, you have to occasionally actually refuse to cover a pricey drug, then weather the resulting public outcry from very sick patients who are desperate to have any treatment, whatever the cost.

The astute reader will by now have noticed that what Trump is proposing is actually a step toward what people wanted the government to do when they said “let Medicare negotiate drug prices” — even though it’s not very much at all like what they imagined would happen when Medicare negotiated. This astute reader will also have noticed, however, that it’s at best only a half-step. Drug plans will still have only limited ability to say “Sorry about your cancer, but we’re just not paying $300,000 to buy you another few months of life.”

It’s not really surprising that they’re only willing to take a half-step. Most American health-care reform proposals look a lot like this one: Emulate some practice that’s common in other countries, only weaken it so that it’s not nearly as effective as what those countries do. You may be surprised to learn that the reason for this halfheartedness is not that the health-care industry has especially charming lobbyists. No, the real villain in our health-care saga is not K Street, but <a href="https://www.bloomberg.com/view/articles/2018-05-13/trump-drug-plan-shows-why-high-prices-persist">the American voting public</a>.

People in other countries seem reasonably willing to trust that if their government says a drug isn’t worth it, then they don’t need it. Americans tend to think that they are entitled to second-guess the government at every turn. Our health-care system reflects that: We give doctors immense autonomy to prescribe any course of treatment they can think up, without some regulator tut-tutting over the national formulary. Unfortunately, that autonomy comes at a price. Almost 20 percent of gross domestic product, in fact.

And maybe we shouldn’t say no. We are, after all, an incredibly rich country. If it costs us a boatload of money to buy marginal life extensions for American citizens, who’s to say that’s not money well spent?

But even if you believe we ought to say no more often, you’re not going to get very far with that belief unless you can convince a whole lot of voters. In theory, Americans may be all for a cheaper health-care system. In practice, when anyone tries to limit their choices, they stampede to the nearest legislator with outraged complaints. Until that mind-set changes, baby steps forward are about the best we can do — which means that for the foreseeable future, we’ll continue to have the most expensive health-care system in the world.

The Up Side of Down: Why Failing Well Is the Key to Success

Megan McArdle is a Washington Post columnist and the author of "<a href="https://www.amazon.com/gp/product/0143126369/ref=as_li_qf_asin_il_tl?ie=UTF8&tag=thewaspos09-20&creative=9325&linkCode=as2&creativeASIN=0143126369&linkId=81f062af99d4715d7ed5ca96b18dc573">The Up Side of Down: Why Failing Well Is the Key to Success</a>."

Megan McArdle

The Washington Post

name

PostPartisan

Quick takes by The Post's opinion writers.

Opinions to start the day, in your inbox. Sign up.

Opinions

The Washington Post Opinions section features opinion articles, op-eds, editorials by the Editorial Board, global opinions and letters to the editor on the issues of the day. Offerings include columns by Washington Post opinion writers, political cartoons by editorial cartoonists Ann Telnaes and Michael de Adder and podcasts by James Hohmann and Jonathan Capehart.